With their recent tie-up, Abbott and Genset are well-placed to exploit this.

ECONOMIST: Biotechnology

Genset (nasdaq: GENXY - news - people), Lexicon Genetics (nasdaq: LEXG - news - people) and Curagen (nasdaq: CRGN - news - people) have all announced being at various stages of obesity-drug development.

FORBES: Magazine Article